These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16925502)

  • 1. Cost-effectiveness of atypical antipsychotic medications versus conventional medication.
    Hanrahan P; Luchins DJ; Fabian R; Tolley G
    Expert Opin Pharmacother; 2006 Sep; 7(13):1749-58. PubMed ID: 16925502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In the aftermath of CATIE: how should administrators value atypical antipsychotic medications?
    Luchins DJ
    Adm Policy Ment Health; 2006 Sep; 33(5):541-3. PubMed ID: 16688482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.
    Achilla E; McCrone P
    Appl Health Econ Health Policy; 2013 Apr; 11(2):95-106. PubMed ID: 23494934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of atypicals in the UK.
    Heeg B; Buskens E; Botteman M; Caleo S; Ingham M; Damen J; de Charro F; van Hout B
    Value Health; 2008 Dec; 11(7):1007-21. PubMed ID: 18489517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials.
    Lieberman JA
    J Clin Psychiatry; 2007 Feb; 68(2):e04. PubMed ID: 17335312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial-based cost-effectiveness analyses of antipsychotic use.
    Polsky D; Doshi JA; Bauer MS; Glick HA
    Am J Psychiatry; 2006 Dec; 163(12):2047-56. PubMed ID: 17151153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of atypical antipsychotics in chronic schizophrenia.
    Amin S
    Hosp Med; 1999 Jun; 60(6):410-3. PubMed ID: 10492711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of atypical antipsychotics in the management of schizophrenia.
    Campbell M; Young PI; Bateman DN; Smith JM; Thomas SH
    Br J Clin Pharmacol; 1999 Jan; 47(1):13-22. PubMed ID: 10073734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of atypical versus typical antipsychotic medication on earnings of schizophrenia patients : estimates from a prospective naturalistic study.
    Salkever D; Slade E; Karakus M
    Pharmacoeconomics; 2006; 24(2):123-39. PubMed ID: 16460134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The new atypical antipsychotics: a review of pharmacoeconomic studies.
    Revicki DA
    Expert Opin Pharmacother; 2000 Jan; 1(2):249-60. PubMed ID: 11249546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of atypical antipsychotics on quality of life in patients with schizophrenia.
    Awad AG; Voruganti LN
    CNS Drugs; 2004; 18(13):877-93. PubMed ID: 15521791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy.
    Davies LM; Lewis S; Jones PB; Barnes TR; Gaughran F; Hayhurst K; Markwick A; Lloyd H;
    Br J Psychiatry; 2007 Jul; 191():14-22. PubMed ID: 17602120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic safety and efficacy concerns.
    Meyer JM
    J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia.
    Revicki DA
    Schizophr Res; 1999 Mar; 35 Suppl():S101-9. PubMed ID: 10190231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs.
    Tunis SL; Ascher-Svanum H; Stensland M; Kinon BJ
    Pharmacoeconomics; 2004; 22(1):1-8. PubMed ID: 14720078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals.
    Essock SM; Frisman LK; Covell NH; Hargreaves WA
    Arch Gen Psychiatry; 2000 Oct; 57(10):987-94. PubMed ID: 11015817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical antipsychotics in the managed care era.
    Loebel AD; Botts SR; Feldman BI
    Am J Manag Care; 1998 Jan; 4 Suppl():S37-50; quiz S51-2. PubMed ID: 10181074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of antipsychotic medication on psychiatric service utilization and cost.
    Rothbard A; Murrin MR; Jordan N; Kuno E; McFarland BH; Stroup TS; Morrissey JP; Stiles PG; Boothroyd RA; Merwin E; Shern DL
    J Ment Health Policy Econ; 2005 Jun; 8(2):83-93. PubMed ID: 15998980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.